The fair value of Soligenix, a micro-cap pharmaceutical company, is estimated to be 800% higher than the current share price, according to a recent report by Zacks Small-Cap Research (Zacks SCR). Soligenix is developing several products, chief among which is a vaccine for the deadly, hemorrhagic-fever-causing Marburg virus. It is…